Compare Travere Therapeutics Inc. Common Stock (TVTX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs 22nd Century Group Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 10253.2× 22nd Century Group Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| TVTX | XXII | |
|---|---|---|
Market Cap | $4.88B | $475.95K |
Volume | 1,668,577 | 78,911 |
Sector | Health | Consumer Staples |
52-Week High | $67.52 | $483.00 |
52-Week Low | $26.79 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.01B | -$3.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
